NEW YORK, NY / ACCESSWIRE / March 10, 2021 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of ACADIA Pharmaceuticals Inc. ("ACADIA" or "the Company") (NASDAQ:ACAD). Investors who purchased ACADIA securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: www.bgandg.com/acad.
The investigation concerns whether ACADIA and certain of its officers and/or directors have violated federal securities laws.
On March 8, 2021, post-market, Acadia issued a press release providing a regulatory update on the Company's supplemental New Drug Application ("NDA") for Pimavanserin for the treatment of hallucinations and delusions associated with dementia-related psychosis, disclosing "that the Company received a notification from the U.S. Food and Drug Administration (FDA) on March 3, 2021, stating that, as part of its ongoing review of the Company's supplemental New Drug Application (sNDA), the FDA has identified deficiencies that preclude discussion of labeling and post-marketing requirements/commitments at this time." Acadia advised that "[t]he notification does not specify the deficiencies identified by the FDA and there has been no clarification by the FDA at this time." On this news, Acadia's stock price fell sharply during intraday trading on March 9, 2021.
If you are aware of any facts relating to this investigation, or purchased ACADIA shares, you can assist this investigation by visiting the firm's site: www.bgandg.com/acad. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484
[email protected]
SOURCE: Bronstein, Gewirtz & Grossman, LLC